Lymphocytic Leukemia, Chronic Clinical Trial
Official title:
A Phase Ib Multicenter Dose-Finding and Safety Study of Venetoclax and Obinutuzumab in Patients With Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Verified date | January 2020 |
Source | Genentech, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics as well as the preliminary efficacy of venetoclax (GDC-0199; ABT-199) administered in combination with obinutuzumab to participants with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL). The study is comprised of two stages for each participant population: a dose-finding stage and a safety-expansion stage. The dose-finding stage will explore multiple doses of venetoclax to be used in combination with a fixed dose of obinutuzumab. The dose-finding stage will also explore two schedules for drug administration, Schedule A (venetoclax introduced before obinutuzumab) and Schedule B (venetoclax introduced after obinutuzumab).
Status | Completed |
Enrollment | 82 |
Est. completion date | August 23, 2019 |
Est. primary completion date | May 21, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of relapsing/refractory or previously untreated chronic lymphocytic leukemia - Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to (</=) 1 - Adequate bone marrow function - Adequate coagulation, renal and hepatic function - For all participants, agreement to remain abstinent or use contraceptive methods that result in a failure rate of less than (<) 1% per year during the treatment period and for at least 90 days (30 days for women) after the last dose of venetoclax or 18 months after the last dose of obinutuzumab, whichever is longer Exclusion Criteria: - Participants who have undergone allogenic stem cell transplant are ineligible unless they meet the following criteria, a) participants who are off all immunosuppressive therapy, b) participants who have no signs and/or symptoms of acute or chronic graft versus host disease, or c) participants must have appropriate hematology counts - Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C - Uncontrolled autoimmune hemolytic anemia or thrombocytopenia - Investigational or anti-cancer therapy within 5 half-lives prior to the first dose of study drug - History of significant renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease |
Country | Name | City | State |
---|---|---|---|
United Kingdom | St James University Hospital | Leeds | |
United Kingdom | Leicester Royal Infirmary NHS Trust | Leicester | |
United Kingdom | Barts and The London School of Medicine and Dentistry; Queen Mary, University of London | London | |
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
United States | Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center | Denver | Colorado |
United States | The Methodist Hospital Research Institute; Academic Office of Clinical Trials | Houston | Texas |
United States | UCSD Moores Cancer Center | La Jolla | California |
United States | SCRI-Tennessee Oncology | Nashville | Tennessee |
United States | Weill Cornell Medical College-New York Presbyterian Hospital | New York | New York |
United States | Oncology Associates of Oregon | Springfield | Oregon |
Lead Sponsor | Collaborator |
---|---|
Genentech, Inc. | AbbVie (prior sponsor, Abbott) |
United States, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Dose Limiting Toxicities (DLTs) | Schedule (Sch) A (Cycle 1 Day 1 to Day 21), Sch B (Cycle 1 Day 22 to Cycle 2 Day 28) (1 Cycle=28 days) | ||
Primary | Maximum Tolerated Dose (MTD) of Venetoclax in Combination with Obinutuzumab | Sch A (Cycle 1 Day 1 to Day 21), Sch B (Cycle 1 Day 22 to Cycle 2 Day 28) (1 Cycle=28 days) | ||
Secondary | Percentage of Participants with Adverse Events | Baseline up to end of study (up to approximately 5 years and 5 months) | ||
Secondary | Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) to Obinutuzumab | Baseline up to Cycle 6 (1 Cycle=28 days) | ||
Secondary | Area Under the Concentration-Time Curve (AUC) of Venetoclax | Baseline up to Cycle 6 (1 Cycle=28 days) | ||
Secondary | Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax | Baseline up to Cycle 6 (1 Cycle=28 days) | ||
Secondary | Maximal Plasma Concentration (Cmax) of Venetoclax | Baseline up to Cycle 6 (1 Cycle=28 days) | ||
Secondary | Minimum Plasma Concentration (Cmin) of Venetoclax | Baseline up to Cycle 6 (1 Cycle=28 days) | ||
Secondary | Cmax of Obinutuzumab | Baseline up to Cycle 6 (1 Cycle=28 days) | ||
Secondary | Cmin of Obinutuzumab | Baseline up to Cycle 6 (1 Cycle=28 days) | ||
Secondary | Percentage of Participants with Confirmed Complete Response (CR) as Determined by Standard CLL Response Criteria | Baseline up to end of study (up to approximately 5 years and 5 months) | ||
Secondary | Percentage of Participants with Objective Response (Partial Response [PR] or CR [Including Cytopenic CR] as Determined by Standard CLL Response Criteria | Baseline up to end of study (up to approximately 5 years and 5 months) | ||
Secondary | Duration of Objective Response as Determined by Standard CLL Response Criteria | Baseline up to end of study (up to approximately 5 years and 5 months) | ||
Secondary | Overall Survival | Baseline up to death or end of study (up to approximately 5 years and 5 months) | ||
Secondary | Progression-Free Survival as Determined by Standard CLL Response Criteria | Baseline up to end of study (up to approximately 5 years and 5 months) | ||
Secondary | Change from Baseline in Number of B-Cells | Baseline up to end of study (up to approximately 5 years and 5 months) | ||
Secondary | Change from Baseline in Number of T-Cells | Baseline up to end of study (up to approximately 5 years and 5 months) | ||
Secondary | Change from Baseline in Number of Natural Killer (NK) Cells | Baseline up to end of study (up to approximately 5 years and 5 months) | ||
Secondary | Change from Baseline in Serum Immunoglobulin Level | Baseline up to end of study (up to approximately 5 years and 5 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01072240 -
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia
|
N/A | |
Completed |
NCT00754650 -
A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT02500407 -
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04704323 -
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
|
||
Active, not recruiting |
NCT01414205 -
A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GAGE)
|
Phase 2 | |
Completed |
NCT01224093 -
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
|
N/A | |
Completed |
NCT01395615 -
An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia
|
N/A | |
Completed |
NCT00532129 -
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
|
Phase 2 | |
Completed |
NCT02013817 -
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
|
Phase 2 | |
Completed |
NCT00738374 -
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
|
Phase 2 | |
Completed |
NCT00241358 -
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01056510 -
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
|
Phase 4 | |
Completed |
NCT01300247 -
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
|
Phase 1 | |
Terminated |
NCT01271010 -
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
|
Phase 4 | |
Completed |
NCT00718549 -
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
|
Phase 3 | |
Completed |
NCT01263704 -
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT00431873 -
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT01178086 -
A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
|
||
Terminated |
NCT02292225 -
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
|
Phase 1 | |
Completed |
NCT02533401 -
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
|
Phase 2 |